Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DRMA 
Dermata Therapeutics Inc (DRMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.96% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.02M USD | Price to earnings Ratio 0.28 | 1Y Target Price 10 |
Price to earnings Ratio 0.28 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 0.56 | 52 Weeks Range 5.04 - 23.00 | Updated Date 09/17/2025 |
52 Weeks Range 5.04 - 23.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 20.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -110.91% | Return on Equity (TTM) -231.27% |
Valuation
Trailing PE 0.28 | Forward PE - | Enterprise Value -2456336 | Price to Sales(TTM) - |
Enterprise Value -2456336 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 681557 | Shares Floating 498470 |
Shares Outstanding 681557 | Shares Floating 498470 | ||
Percent Insiders 17 | Percent Institutions 7.46 |
Upturn AI SWOT
Dermata Therapeutics Inc
Company Overview
History and Background
Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing and commercializing innovative treatments for dermatological diseases and conditions. Founded in 2014, Dermata has focused on leveraging innovative delivery systems for established active ingredients to create differentiated products.
Core Business Areas
- Acne Vulgaris: Developing treatments for acne, a common skin condition affecting millions.
- Rosacea: Developing treatments for rosacea, a chronic inflammatory skin condition.
- Psoriasis: Exploring treatments for psoriasis, an autoimmune condition affecting the skin.
Leadership and Structure
Dermata Therapeutics is led by a management team with experience in dermatology and pharmaceutical development. The company operates with a typical biotech organizational structure, emphasizing research and clinical development.
Top Products and Market Share
Key Offerings
- DMT310: DMT310 is the primary product candidate, a once-daily topical product for the treatment of acne. The compound inhibits sebum production. Competitors include oral isotretinoin brands like Accutane (now generic), topical retinoids, and other acne treatments. Revenue is currently $0, in the clinical trial phase.
- DMT410: DMT410 is a product for treating rosacea. Competitors for this product include topical medications such as metronidazole, azelaic acid, and brimonidine. Revenue is currently $0, in the clinical trial phase.
Market Dynamics
Industry Overview
The dermatology market is driven by high prevalence of skin conditions and growing demand for effective treatments. It is a large and competitive market with numerous players, including established pharmaceutical companies and emerging biotech firms.
Positioning
Dermata Therapeutics aims to differentiate itself through innovative delivery systems and formulations of existing drugs. Their competitive advantage lies in potentially improving efficacy and tolerability compared to existing treatments.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth hundreds of billions of dollars. Dermata is focused on specific segments within this market, and its TAM is dependent on the successful development and commercialization of its product candidates. Their DMT310 candidate aims to target the approximate 5.1 billion USD acne market.
Upturn SWOT Analysis
Strengths
- Innovative delivery system technology
- Experienced management team
- Targeting large dermatology markets
- Potential for improved efficacy and tolerability
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited financial resources
Opportunities
- Successful clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new dermatology indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from established treatments
- Regulatory hurdles
- Patent challenges
- Lack of Funding
Competitors and Market Share
Key Competitors
- VRX
- ALLY
- ALNY
- GRTS
- MRTX
Competitive Landscape
Dermata Therapeutics is a small player in a competitive market. Its success depends on demonstrating superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is negligible given their clinical stage.
Future Projections: Future growth is highly dependent on clinical trial results and regulatory approvals. Analyst estimates are based on projected sales of potential products.
Recent Initiatives: Focus is on advancing DMT310 and DMT410 through clinical trials. The company continues to seek funding to support its development programs.
Summary
Dermata Therapeutics is a clinical-stage biotech company with innovative delivery system technologies in the dermatology space. Its financial situation depends heavily on positive clinical trial results. The company is risky, but with great potential. Cash flow issues and trial failures are its main vulnerabilities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Yahoo Finance
- Other Online Stock Market News
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies involves significant risk. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.